Myricx is headquartered in London and focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs), based on inhibitors of the enzymes, N-myristoyltransferases (NMT) for the treatment of cancer.
Myricx is progressing a pipeline of proprietary differentiated ADCs based on our novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.
Based on compelling preclinical efficacy and safety data across multiple solid tumour-associated antigens and cancer cell types are prioritising two proprietary, differentiated NMTi-ADCs that target the cancer associated antigens – B7-H3 and HER2.
